Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
Athanasios D Anastasilakis,1 Konstantinos A Toulis,1 Stergios A Polyzos,2 Chrysostomos D Anastasilakis,3 Polyzois Makras41Department of Endocrinology, 424 General Military Hospital, 2Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, 3Department of Pha...
Main Authors: | Anastasilakis AD, Toulis KA, Polyzos SA, Anastasilakis CD, Makras P |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-06-01
|
Series: | Therapeutics and Clinical Risk Management |
Online Access: | http://www.dovepress.com/long-term-treatment-of-osteoporosis-safety-and-efficacy-appraisal-of-d-a10154 |
Similar Items
-
Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation
by: Athanasios D. Anastasilakis, et al.
Published: (2020-06-01) -
Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
by: Athanasios D. Anastasilakis, et al.
Published: (2021-01-01) -
Safety and efficacy of denosumab in postmenopausal somen with osteoporosis
by: Dilsad Sindel, et al.
Published: (2020-10-01) -
Investigating Denosumab discontinuation in the TgRANKL osteoporotic mouse model
by: Vagelis Rinotas, et al.
Published: (2021-04-01) -
Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients
by: Polyzois Makras, et al.
Published: (2021-12-01)